Level B· Emerging clinical evidence with positive signalsRandomized Controlled TrialPubMed

Randomized clinical trial: effect of low-dose flutamide on abdominal adipogenic function in normal-weight women with polycystic ovary syndrome.

Dumesic DA., Winnett C., Lu G., Grogan TR., Abbott DH., Naik R.

Randomized Controlled Trial on Systemic / IV, published in Fertil Steril (2022) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
Fertil Steril (2022)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
36400597
PMCID
PMC12036725
DOI
10.1016/j.fertnstert.2022.09.324
NCT
NCT01889199
Citations
13

Abstract (original English)

Objective To examine whether low-dose flutamide administration to normal-weight women with polycystic ovary syndrome (PCOS) reduces abdominal fat deposition, attenuates accelerated lipid accumulation in newly formed adipocytes derived from subcutaneous (SC) abdominal adipose stem cells (ASCs), and/or alters glucose-lipid metabolism. Design A double-blind, placebo-controlled randomized clinical trial. Setting An academic medical center. Patient(s) Twelve normal-weight women with PCOS and 12 age- and body mass index-matched controls. Intervention(s) Women underwent circulating hormonal and metabolic determinations, intravenous glucose tolerance testing, total body dual-energy roentgenogram absorptiometry, and SC abdominal fat biopsy. Interventions were repeated in women with PCOS after 6-month administration of flutamide (125 mg orally daily) vs. placebo. Main outcome measure(s) Clinical parameters and lipid accumulation in newly formed adipocytes derived from SC abdominal ASCs in vitro were compared between controls and the women with PCOS receiving flutamide vs. placebo. Results Serum luteinizing hormone and androgen levels as well as lipid accumulation in newly formed SC abdominal adipocytes were greater in the women with PCOS than controls. Flutamide vs. placebo reduced percent android fat, lowered serum log low-density lipoprotein and log non-high-density lipoprotein levels,

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
FemaleHumansFlutamideGlucoseLipidsLipoproteinsLipoproteins, LDLPolycystic Ovary Syndrome

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research